|
|
Volumn 361, Issue 9352, 2003, Pages 182-184
|
|
Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility [10] (multiple letters)
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DEFERIPRONE;
DEFEROXAMINE;
DEOXYHEMOGLOBIN;
DIPYRIDAMOLE;
IRON;
IRON CHELATING AGENT;
PYRIDONE DERIVATIVE;
ANEMIA;
BIOPSY;
BLOOD OXYGENATION;
CAPILLARY DENSITY;
CARDIOMYOPATHY;
CHELATION THERAPY;
CLINICAL PRACTICE;
CORRELATION ANALYSIS;
CORRELATION COEFFICIENT;
DOSE RESPONSE;
DRUG EFFICACY;
DRUG ELIMINATION;
DRUG HALF LIFE;
FERRITIN BLOOD LEVEL;
HEART;
HEART FAILURE;
HEART FUNCTION;
HEART MUSCLE;
HEART MUSCLE BIOPSY;
HEART MUSCLE FIBROSIS;
HUMAN;
IRON CHELATION;
IRON INTAKE;
IRON OVERLOAD;
LETTER;
LIVER;
MYOCARDIAL DISEASE;
NUCLEAR MAGNETIC RESONANCE IMAGING;
PRIORITY JOURNAL;
THALASSEMIA MAJOR;
TREATMENT OUTCOME;
BETA THALASSEMIA;
DRUG EFFECT;
METABOLISM;
NOTE;
ORAL DRUG ADMINISTRATION;
STATISTICAL MODEL;
SUBCUTANEOUS DRUG ADMINISTRATION;
ANIMAL;
ADMINISTRATION, ORAL;
BETA-THALASSEMIA;
DEFEROXAMINE;
HEART;
HUMANS;
INJECTIONS, SUBCUTANEOUS;
IRON CHELATING AGENTS;
LINEAR MODELS;
LIVER;
PYRIDONES;
ANIMALS;
|
|
EID: 0037431751
PISSN: 01406736
EISSN: None
Source Type: Journal
DOI: 10.1016/s0140-6736(03)12221-0 Document Type: Letter |
|
Times cited : (23)
|
|
References (4)
|
